Trojan Bio
Harnessing viral specific immunity for fighting cancer
Yavne, Israel · Founded 2021 · $904K raised
- Headquarters
- Yavne
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- trojan-bio.com
- Total Funding
- $904K
- Last Round
- GrantJan 2023
- Rounds
- 3
About
Trojan Bio is developing a novel class of therapeutic antibodies for the treatment of solid tumors. The company's Trojan antibody platform integrates viral peptides into antibody structures, enabling them to penetrate tumor microenvironments and activate the immune system from within—harnessing antiviral immunity to fight cancer. Trojan Bio won the Biomed Israel 2025 Startup Competition and is backed by Peregrine Ventures.
Summary
Trojan Bio is a Biotech company based in Yavne, Israel, founded in 2021. It has raised $904K in total across 3 rounds, most recently a Grant round in Jan 2023. Investors include NFX, Peregrine Ventures and Israel Innovation Authority.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.